|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Robert Erik Holmlin||Pres, CEO, Sec. & Director||519,07k||N/D||1968|
|Mr. Christopher P. Stewart||Chief Financial Officer||77,93k||N/D||1970|
|Mr. Mark Oldakowski||Chief Operating Officer||376,1k||N/D||1974|
|Dr. Alka Chaubey FACMG, Ph.D.||Chief Medical Officer||N/D||N/D||1973|
|Mr. Robert J. Priar||Chief Commercial Officer||N/D||N/D||N/D|
|Mr. Richard Shippy||Chief Bus. Officer||N/D||N/D||N/D|
|Dr. Soheil Shams Ph.D.||Chief Informatics Officer||N/D||N/D||N/D|
|Dr. Paul R. Selvin Ph.D.||Scientific Advisor||N/D||N/D||N/D|
|Prof. Pui-Yan Kwok M.D., Ph.D.||Scientific Advisor||N/D||N/D||N/D|
Bionano Genomics, Inc., a genome analysis company, provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Its Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables scientists and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. The company also provides diagnostic testing for those with autism spectrum disorder and other neurodevelopmental disabilities. In addition, it offers an agnostic cross-platform data interpretation and clinical reporting software that integrates next-generation sequencing and microarray data, and provides visualization of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome for a fully integrated analysis in one view. The company was founded in 2006 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Bionano Genomics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.